Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

BACKGROUND: Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several predictive factors of gefitinib sensitivity have been well described. However, few studies have investigated the clinical fea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yokouchi, Hiroshi, Yamazaki, Koichi, Kinoshita, Ichiro, Konishi, Jun, Asahina, Hajime, Sukoh, Noriaki, Harada, Masao, Akie, Kenji, Ogura, Shigeaki, Ishida, Takashi, Munakata, Mitsuru, Dosaka-Akita, Hirotoshi, Isobe, Hiroshi, Nishimura, Masaharu
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2007
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1838917/
https://ncbi.nlm.nih.gov/pubmed/17374153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-7-51
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge